A polymorphism of EGFR extracellular domain is associated with progression free-survival in metastatic colorectal cancer patients receiving cetuximab-based treatment

BACKGROUND: Cetuximab, a monoclonal antibody targeting Epidermal Growth Factor Receptor (EGFR), is currently used in metastatic colorectal cancer (mCRC), but predictive factors for therapeutic response are lacking. Mutational status of KRAS and EGFR, and EGFR copy number are potential determinants o...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Glavni autori: Gonçalves, Anthony, Esteyries, Séverine, Taylor-Smedra, Brynn, Lagarde, Arnaud, Ayadi, Mounay, Monges, Geneviève, Bertucci, François, Esterni, Benjamin, Delpero, Jean-Robert, Turrini, Olivier, Lelong, Bernard, Viens, Patrice, Borg, Jean-Paul, Birnbaum, Daniel, Olschwang, Sylviane, Viret, Frédéric
Format: Artigo
Jezik:Inglês
Izdano: BioMed Central 2008
Teme:
Research Article
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC2432064/
https://ncbi.nlm.nih.gov/pubmed/18544172
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1471-2407-8-169
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items